To describe the outcome of CAR-T therapy in relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Retrospective analysis of CAR-T therapy outcome in DLBCL, in a single center. The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas. Between November 2020 and December 2022, a total of 25 patients with relapsed or refractory DLBCL to ≥2 lines of therapy received an infusion and were included in the analysis. Of the 25 patients, 64% were male, the median age was 48 (20-73), and ECOG was 0-1. The disease subtype includes germinal center B-cell (GCB) 52% (n=12) and activated B-cell (ABC) 48% (n=12); the disease stage was III (44%, n=11) and IV (52%, n=13). All patients received at least 2 lines of therapy; 52% received ≥ 3 lines. Relapsed after autologous stem cell transplantation in 24% (n=6). Three patients (12%) have CNS involvement which was controlled at the infusion time. All patients received lymphodepletion (LD) therapy with fludarabine and cyclophosphamide (Flu/Cy). 20% (n=5) required bridging therapy before LD. Overall response rate (ORR), complete responses (CR), partial responses (PR). The respective toxicities include cytokine release syndrome (CRS) and neurologic events namely ICANS. The best ORR was 52%; 32% of the patients had CR, and 20% had PR. The disease progression (DP) was 48%. The 2 years overall survival was 72% with 69.2% for GCB subtype. Overall progressive free survival (PFS) was 44%, and the best PFS was observed in GCB subtype 53.8%. Day-90 PET/CT ORR 44% (CR/PR) 36%/8%. DP at day 90 was 36%. The main toxicities post CAR-T cell infusion including cytokines release syndrome (CRS) was 88% with 12% grade ≥ 3, and the neurotoxicity (NT) namely was 24% with 20% grade ≥ 3. Tocilizumab was used in 60%. Two patients died from disease progression within 30 days after infusion. In this single-center retrospective analysis of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, the rates of durable responses were like the real-world data and JULIET NCT02445248 trial outcome using tisagenlecleucel therapy